Patents by Inventor Cammie LESSER

Cammie LESSER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10702559
    Abstract: Described herein are compositions and methods relating to engineered bacteria which have a modified Type 3 Secretion System (T3SS) which permits them to deliver proteins to the extracellular space (e.g., as opposed to the intracellular space of a target cell as done with a wild-type T3SS). In some embodiments, the engineered bacteria comprise a transgenic T3SS. In some embodiments, the delivered protein is non-native or transgenic with respect to the engineered bacteria.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: July 7, 2020
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Cammie Lesser, Analise Reeves
  • Publication number: 20190055569
    Abstract: The methods and compositions described herein relate to the delivery of polypeptides to a target cell, e.g. by utilizing engineered non-pathogenic bacteria comprising a type three secretion system (T3SS) and T3SS-compatible substrates. In one aspect, described herein are non-pathogenic microbial cells that have been engineered to express both a functional type three secretion system (T3SS) and at least one polypeptide that is compatible with the T3SS. Due to the wide variety of polypeptides that can be delivered to a target eukaryotic cell using the compositions and systems described herein, a commensurately wide variety of applications is contemplated, e.g. therapeutics and reprogramming.
    Type: Application
    Filed: March 9, 2018
    Publication date: February 21, 2019
    Applicants: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Cammie LESSER, Amy Jo Wagers, Analise Z. Reeves
  • Publication number: 20190038679
    Abstract: Described herein are compositions and methods relating to engineered bacteria which have a modified Type 3 Secretion System (T3SS) which permits them to deliver proteins to the extracellular space (e.g., as opposed to the intracellular space of a target cell as done with a wild-type T3SS). In some embodiments, the engineered bacteria comprise a transgenic T3SS. In some embodiments, the delivered protein is non-native or transgenic with respect to the engineered bacteria.
    Type: Application
    Filed: February 8, 2017
    Publication date: February 7, 2019
    Applicant: THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL
    Inventors: Cammie LESSER, Analise REEVES
  • Patent number: 9951340
    Abstract: The methods and compositions described herein relate to the delivery of polypeptides to a target cell, e.g. by utilizing engineered non-pathogenic bacteria comprising a type three secretion system (T3SS) and T3SS-compatible substrates. In one aspect, described herein are non-pathogenic microbial cells that have been engineered to express both a functional type three secretion system (T3SS) and at least one polypeptide that is compatible with the T3SS. Due to the wide variety of polypeptides that can be delivered to a target eukaryotic cell using the compositions and systems described herein, a commensurately wide variety of applications is contemplated, e.g. therapeutics and reprogramming.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: April 24, 2018
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Cammie Lesser, Amy Jo Wagers, Analise Z. Reeves
  • Publication number: 20160046951
    Abstract: The methods and compositions described herein relate to the delivery of polypeptides to a target cell, e.g. by utilizing engineered non-pathogenic bacteria comprising a type three secretion system (T3SS) and T3SS-compatible substrates. In one aspect, described herein are non-pathogenic microbial cells that have been engineered to express both a functional type three secretion system (T3SS) and at least one polypeptide that is compatible with the T3SS. Due to the wide variety of polypeptides that can be delivered to a target eukaryotic cell using the compositions and systems described herein, a commensurately wide variety of applications is contemplated, e.g. therapeutics and reprogramming.
    Type: Application
    Filed: March 6, 2014
    Publication date: February 18, 2016
    Inventors: Cammie LESSER, Amy Jo WAGERS, Analise Z. REEVES